Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer.
Συγγραφείς:	Tarantino P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Paolo_Tarantino@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. Paolo_Tarantino@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Paolo_Tarantino@dfci.harvard.edu., Cha J; Harvard Medical School, Boston, MA, USA., Binboga Kurt B; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Chu X; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Jovanović B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Loxo@Lilly, Indianapolis, IN, USA., Zhou A; Harvard Medical School, Boston, MA, USA., Hughes M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Russo D; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., DiLullo M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wrabel E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Jeselsohn R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Carter J; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Chen YS; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Li T; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Tayob N; Harvard Medical School, Boston, MA, USA.; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Schnitt SJ; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Goel S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Πηγή:	NPJ breast cancer [NPJ Breast Cancer] 2026 Feb 13; Vol. 12 (1). Date of Electronic Publication: 2026 Feb 13.
Τύπος έκδοσης:	Journal Article
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE
Imprint Name(s):	Original Publication: New York, NY : Breast Cancer Research Foundation : Nature Publishing Group, [2015]-
Περίληψη:	HER2-low expression is associated with hormone receptor (HR) expression in HR-positive breast cancer. We aimed to evaluate its association with androgen receptor (AR) among 196 patients with metastatic triple-negative breast cancer (mTNBC). Central determination of AR showed significant enrichment in HER2-low compared with HER2-0 mTNBC (mean: 33.7% vs. 21.4%, p = 0.038), whereas no significant immunological differences were observed. HER2-low/AR-positive patients trended towards longer overall survival, highlighting the potential relevance of these biomarkers. (© 2026. The Author(s).)
Competing Interests:	Competing interests: P.T. reports consulting fees from AstraZeneca, Daiichi Sankyo, Gilead, Genentech/Roche, Novartis, Menarini/Stemline, and Eli Lilly. NUL reports institutional research support from Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, and AstraZeneca; consulting honoraria from Seattle Genetics, Daiichi Sankyo, AstraZeneca, Olema Pharmaceuticals, Stemline/Menarini, Artera Inc., Eisai, and Shorla Oncology; royalties from Up to date (book); and travel support from Olema Pharmaceuticals, AstraZeneca, and Daiichi Sankyo. SMT reports consulting or advisory roles for Novartis, Pfizer/SeaGen, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Bristol Myers Squibb/Systimmune, Daiichi Sankyo, Gilead, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Artios Pharma, Menarini/Stemline, Aadi Bio, Bayer, Jazz Pharmaceuticals, Natera, Tango Therapeutics, eFFECTOR, Hengrui USA, Cullinan Oncology, Circle Pharma, Arvinas, BioNTech, Johnson&Johnson/Ambrx, Launch Therapeutics, Zuellig Pharma, Bicycle Therapeutics, BeiGene Therapeutics, Mersana, Summit Therapeutics, Avenzo Therapeutics, Aktis Oncology, Celcuity, Boehringer Ingelheim, Samsung Bioepis, Olema Pharmaceuticals, Tempus, and Boundless Bio; institutional research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, OncoPep, Daiichi Sankyo, Menarini/Stemline, Jazz Pharmaceuticals, and Olema Pharmaceuticals; and travel support from Eli Lilly, Gilead, Jazz Pharmaceuticals, Pfizer, Arvinas, and Roche.
References:	JAMA Oncol. 2023 Apr 1;9(4):500-510. (PMID: 36821125) J Breast Cancer. 2025 Feb;28(1):23-36. (PMID: 40047088) Lancet Oncol. 2021 Aug;22(8):1151-1161. (PMID: 34252375) Cancers (Basel). 2021 Dec 01;13(23):. (PMID: 34885167) J Clin Oncol. 2020 Jun 10;38(17):1951-1962. (PMID: 32330069) NPJ Breast Cancer. 2019 Dec 10;5:47. (PMID: 31840050) Breast Cancer Res. 2024 Mar 11;26(1):41. (PMID: 38468323) N Engl J Med. 2022 Jul 7;387(1):9-20. (PMID: 35665782) EBioMedicine. 2023 May;91:104571. (PMID: 37068349) J Clin Oncol. 2018 Mar 20;36(9):884-890. (PMID: 29373071) Cancer Treat Rev. 2018 Jul;68:102-110. (PMID: 29940524) Ann Oncol. 2015 Feb;26(2):259-71. (PMID: 25214542) Neoplasia. 2008 Jun;10(6):542-8. (PMID: 18516291) Clin Cancer Res. 2013 Oct 1;19(19):5505-12. (PMID: 23965901) Breast. 2025 Dec;84:104584. (PMID: 40991980) JAMA Oncol. 2022 Aug 1;8(8):1177-1183. (PMID: 35737367) ESMO Open. 2023 Aug;8(4):101592. (PMID: 37413762) Breast Cancer Res Treat. 2021 Apr;186(2):317-326. (PMID: 33417085) Clin Cancer Res. 2025 Apr 14;31(8):1427-1436. (PMID: 39908010) Ann Oncol. 2023 Aug;34(8):645-659. (PMID: 37269905)
Entry Date(s):	Date Created: 20260213 Date Completed: 20260325 Latest Revision: 20260813
Update Code:	20260813
PubMed Central ID:	PMC13013833
DOI:	10.1038/s41523-026-00913-4
PMID:	41688468
Βάση Δεδομένων:	MEDLINE

View record at Springer

καταχωρήστε σχόλιο πρώτοι!